Novo Nordisk Reports 0% Stake in Innate Pharma

Innate Pharma SA disclosure: Novo Nordisk A/S filed Schedule 13G/A (Amendment No. 4) reporting 0 shares beneficially owned representing 0.00% of Innate Pharma's ordinary shares.

Accepted by SEC EDGAR 06/22/2026 - 08:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Innate Pharma SA disclosure: Novo Nordisk A/S filed Schedule 13G/A (Amendment No. 4) reporting 0 shares beneficially owned representing 0.00% of Innate Pharma's ordinary shares. The amendment is signed by Karsten Munk Knudsen, Chief Financial Officer, on 06/22/2026.

Insights

Corporate Governance Analyst

Amendment confirms no beneficial ownership reported by Novo Nordisk.

The filing is an administrative Schedule 13G/A amendment showing 0 shares and 0.00% ownership in Innate Pharma as of the signature date. This indicates no current disclosed passive stake under the filing's data.

Investor impact is minimal; subsequent filings would be required to show any acquisition or disposition. Future ownership changes would be disclosed in follow-up Schedule 13D/G filings if material.

Key Figures

Filing type: Schedule 13G/A (Amendment No. 4) Beneficially owned: 0 shares Percent of class: 0.00% +1 more

4 metrics

Filing type Schedule 13G/A (Amendment No. 4) ownership statement for Innate Pharma ordinary shares

Beneficially owned 0 shares Amount beneficially owned reported in Item 4

Percent of class 0.00% Percent of Innate Pharma ordinary shares reported in Item 4

Signature date 06/22/2026 Date the amendment was signed by the CFO

Key Terms

Schedule 13G/A, Beneficial ownership, American Depositary Shares

3 terms

Schedule 13G/A regulatory

"Item 1. (a) Name of issuer: Innate Pharma; filing header shows "SCHEDULE 13G/A""

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Item 4. | Ownership (a) | Amount beneficially owned: 0"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

American Depositary Shares market

"Title of class of securities: Ordinary Shares ... (including ordinary shares represented by American Depositary Shares)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Novo Nordisk report about Innate Pharma (IPHA)?

Novo Nordisk reported 0 shares beneficially owned, equal to 0.00% of Innate Pharma. The Schedule 13G/A Amendment No. 4 is signed by the filer’s CFO on 06/22/2026, indicating the filing date for this ownership statement.

Does the Schedule 13G/A amendment show any voting or dispositive power?

No. The filing lists 0 for sole and shared voting power and 0 for sole and shared dispositive power. All four voting/dispositive fields are reported as zero in the amendment.

Who signed the amendment and when was it signed?

The amendment is signed by Karsten Munk Knudsen, Chief Financial Officer. The signature date shown in the filing is 06/22/2026, which anchors the ownership statement to that date.

What class of Innate Pharma shares is referenced in the filing?

The filing references Innate Pharma’s Ordinary Shares, nominal value €0.05 per share, including ordinary shares represented by American Depositary Shares (CUSIP 45781K105), as the class covered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Innate Pharma SA

(Name of Issuer)

Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)

(Title of Class of Securities)

45781K105

(CUSIP Number)

05/29/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45781K105

1

Names of Reporting Persons

Novo Nordisk A/S

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Innate Pharma SA
(b)	Address of issuer's principal executive offices: 117 Avenue de Luminy, BP 30191, Marseille, France, 13009
Item 2.
(a)	Name of person filing: Novo Nordisk A/S
(b)	Address or principal business office or, if none, residence: Novo Alle 1, DK-2880, Bagsvaerd Denmark
(c)	Citizenship: Denmark
(d)	Title of class of securities: Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)
(e)	CUSIP No.: 45781K105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0.00%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Nordisk A/S

Signature:	/s/ Karsten Munk Knudsen
Name/Title:	Karsten Munk Knudsen, Chief Financial Officer
Date:	06/22/2026